Candel Therapeutics (NASDAQ: CADL) furnishes Q3 2025 results press release

Rhea-AI Filing Summary

Candel Therapeutics, Inc. filed a current report to disclose that it announced its financial results for the quarter ended September 30, 2025. The company issued a press release on November 13, 2025, and that release is included as Exhibit 99.1 to the report.

The disclosure is furnished rather than filed, meaning it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced. The report is signed on behalf of Candel Therapeutics by its President and Chief Executive Officer, Paul Peter Tak, M.D., Ph.D., FMedSci.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

0001841387false00018413872025-11-132025-11-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2025

CANDEL THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40629	52-2214851
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
117 Kendrick St Suite 450
Needham, Massachusetts				02494
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 916-5445

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		CADL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 13, 2025, Candel Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release dated November 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Candel Therapeutics, Inc.
Date:	November 13, 2025	By:	/s/ Paul Peter Tak
			Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer

FAQ

What did Candel Therapeutics (CADL) report in this Form 8-K?

Candel Therapeutics, Inc. reported that it announced its financial results for the quarter ended September 30, 2025, and furnished the related press release as an exhibit.

Which period do the announced Candel Therapeutics (CADL) results cover?

The announced results cover the quarter ended September 30, 2025.

When did Candel Therapeutics (CADL) announce its quarterly financial results?

Candel Therapeutics announced its quarterly financial results on November 13, 2025.

Where can investors find the detailed Candel Therapeutics (CADL) quarterly results?

The detailed results are contained in the press release furnished as Exhibit 99.1 to the report.

Is the Candel Therapeutics (CADL) earnings press release considered filed with the SEC?

The company states that the information in the report, including Exhibit 99.1, is furnished and is not deemed filed or subject to Section 18 liabilities, nor incorporated by reference into other filings unless specifically referenced.

Who signed this Candel Therapeutics (CADL) Form 8-K?

The report was signed on behalf of Candel Therapeutics, Inc. by Paul Peter Tak, M.D., Ph.D., FMedSci, its President and Chief Executive Officer.